1
00:00:00,000 --> 00:00:03,500
Survodutide targets GLP-1 and glucagon receptors.

2
00:00:03,500 --> 00:00:10,167
In liver research, the important question extends beyond how much weight or liver fat changes.

3
00:00:10,167 --> 00:00:15,625
A 2024 randomized phase two trial studied adults with biopsy-confirmed metabolic dysfunction-associated

4
00:00:15,625 --> 00:00:19,875
steatohepatitis, called MASH, and liver fibrosis over 48 weeks.

5
00:00:19,875 --> 00:00:24,958
The primary endpoint was improvement in MASH without worsening of fibrosis.

6
00:00:24,958 --> 00:00:29,625
More participants reached that endpoint with survodutide than with placebo.

7
00:00:29,625 --> 00:00:33,125
Gastrointestinal adverse events were frequent.

8
00:00:33,125 --> 00:00:37,000
Improved inflammation and improved scarring are different outcomes.

9
00:00:37,000 --> 00:00:44,458
A biopsy result at one time point also cannot establish prevention of liver failure or longer survival

10
00:00:44,458 --> 00:00:47,958
without further evidence.